<\/p>\n
A Russian institute developing one of the country’s potential coronavirus vaccines hopes to start its final stage testing in a small section of the general public in mid-August, the RIA news agency<\/a> cited the institute’s director as saying on Monday.<\/p>\n <\/p>\n (People Also Like To Read: <\/strong>12 Institutes Selected for Clinical Trial of COVID-19 Vaccine by ICMR<\/a>)<\/strong><\/em><\/p>\n <\/p>\n Globally, of 19 experimental COVID-19 vaccines in human trials, only two are in final Phase III trials – one by China’s Sinopharm and another by AstraZeneca and the University of Oxford<\/a>. China’s Sinovac Biotech is set to become the third later this month.<\/p>\n <\/p>\n Early results from the first small-scale human trial of the vaccine developed by the Gamaleya Institute in Moscow has shown it to be safe for use, according to a separate RIA report on Sunday.<\/p>\n <\/p>\n “Around 14-15 August, I hope, the small amount of vaccine that we should be able to produce will enter public circulation,” Alexander Ginsburg, the institute’s director, was quoted as saying.<\/p>\n <\/p>\n This will be equivalent to a Phase III trial since people getting the vaccine will remain under the supervision, RIA reported, citing Ginsburg.<\/p>\n <\/p>\n Phase I and Phase II trials typically test the safety of a drug before it enters Phase III trials that test its efficacy on a bigger group of volunteers.<\/p>\n <\/p>\n Human trials of the Gamaleya Institute’s vaccine began on June 18, with nine volunteers receiving one dose, and another nine testing the prospective booster dose.<\/p>\n <\/p>\n The group did not experience any significant side effects and is due to be released from hospital on Wednesday, RIA reported on Sunday, citing a director at the Sechenov University in Moscow<\/a> where the trial took place.<\/p>\n <\/p>\n (You Might Also Like To Read: <\/strong>9 Most Effective Home Remedies For Mouth Ulcers In Children<\/a>)<\/strong><\/em><\/p>\n <\/p>\n